Tivic Health rebrands as Valion Bio; ticker to VBIO; targets BARDA SNS procurement for Entolimod

Valion Bio, Inc.

Corporate name changes to Valion Bio, Inc.; Nasdaq ticker to change from TIVC to VBIO effective April 28, 2026.
Lead asset Entolimod (TLR5 agonist) for Acute Radiation Syndrome has FDA Fast Track, Orphan Drug, and Animal Rule designations.
Engaged with BARDA, DTRA, NIAID for Strategic National Stockpile procurement; potential nine-figure non-dilutive revenue event.
Parallel oncology indication: chemotherapy-induced neutropenia; targeting Phase IIb readiness; market over $22B.
Velocity Bioworks CDMO subsidiary (acquired ~$16.3M) completed 200-fold scale-up; offers independent third-party revenue stream.

item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Valion Bio, Inc.: Changed corporate name from Tivic Health Systems, Inc. to Valion Bio, Inc (effective 2026-04-28).

Change: charter amendment
Effective: 2026-04-28

Exact text from the filing

On April 22, 2026, Tivic Health Systems, Inc. (the “Company”) filed a certificate of amendment (“Certificate of Amendment”) to its amended and restated certificate of incorporation filed with the Delaware Secretary of State to change its corporate name to Valion Bio, Inc. (the “Name Change”), effective as of April 28, 2026.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-003161

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.